Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Moody National Bank Trust Division

Moody National Bank Trust Division decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,760 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $1,456,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in GILD. State Street Corp increased its position in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the period. Wellington Management Group LLP grew its stake in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC increased its holdings in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Geode Capital Management LLC raised its stake in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on GILD shares. Piper Sandler boosted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. UBS Group boosted their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Oppenheimer increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group raised their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Up 0.1 %

Gilead Sciences stock opened at $89.94 on Tuesday. The firm’s 50 day moving average price is $91.94 and its two-hundred day moving average price is $83.54. The firm has a market cap of $112.09 billion, a PE ratio of 999.33, a P/E/G ratio of 2.24 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.42%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock worth $41,902,086 over the last ninety days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.